A tragic incident has occurred in the U.K. involving a 58-year-old nurse named Susan McGowan who passed away after taking two doses of the weight-loss medication tirzepatide, also known as Mounjaro or Zepbound. According to reports, McGowan’s death was attributed to multiple organ failure, septic shock, and pancreatitis, with the Eli Lilly drug listed as a contributing factor on her death certificate.
McGowan had purchased the prescription for tirzepatide online and had taken two low doses of the drug over a period of two weeks. Shortly after her second dose, she began experiencing severe stomach pain and sickness, prompting her to seek treatment at University Hospital Monklands where she had worked for three decades. Unfortunately, her condition worsened, leading to kidney issues, coma, and eventually organ failure.
Tirzepatide is categorized as a GLP-1 receptor agonist, a class of weight-loss drugs that help reduce appetite by inducing a feeling of fullness. Similar to Novo Nordisk’s Ozempic, tirzepatide is known for its effectiveness in weight loss and managing type two diabetes. However, it is also associated with side effects such as vomiting, diarrhea, and nausea, and in rare cases, severe allergic reactions, kidney problems, stomach issues, and thyroid tumors.
Despite these risks, regulatory authorities maintain that the benefits of tirzepatide outweigh the potential drawbacks. The U.K.’s Medicines and Healthcare products Regulatory Authority approved the drug as a weight loss aid in 2023, closely monitoring adverse events through the Yellow Card reporting scheme. While a second death is under investigation for possible links to tirzepatide, no conclusive evidence has been established.
In response to the incident, Dr. Alison Cave, Chief Safety Officer at MHRA, emphasized the organization’s commitment to patient safety and the rigorous assessment of medicines before approval. Eli Lilly, the manufacturer of tirzepatide, also reiterated its dedication to monitoring and reporting safety information for all its products.
As investigations continue into the circumstances surrounding Susan McGowan’s tragic death, it serves as a poignant reminder of the importance of patient safety and thorough evaluation of medication risks and benefits. Our thoughts are with McGowan’s family during this difficult time, and we hope that lessons learned from this incident will contribute to enhanced safety measures in the healthcare industry.
